Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing prevalence of diabetes across the world
3.2.1.2 Rising technological advancements in diabetes care devices
3.2.1.3 Increasing investments by public and private organizations for diabetes care
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of diabetes care devices
3.2.2.2 Rigorous regulatory framework
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technology landscape
3.6 Reimbursement scenario
3.7 Porter’s analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Blood glucose monitoring devices
5.2.1 Self-monitoring blood glucose meters
5.2.2 Continuous glucose monitors
5.2.3 Testing strips
5.2.4 Lancets
5.3 Insulin delivery devices
5.3.1 Insulin pumps
5.3.1.1 Tubed pumps
5.3.1.2 Tubeless pumps
5.3.2 Pens
5.3.2.1 Reusable
5.3.2.2 Disposable
5.3.3 Pen needles
5.3.3.1 Standard
5.3.3.2 Safety
5.3.4 Syringes
5.3.5 Other insulin delivery devices
Chapter 6 Market Estimates and Forecast, By End Use, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Hospital
6.3 Ambulatory surgical centres
6.4 Diagnostic centres
6.5 Homecare
6.6 Other end users
Chapter 7 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 Germany
7.3.2 France
7.3.3 UK
7.3.4 Italy
7.3.5 Spain
7.3.6 Netherlands
7.3.7 Sweden
7.3.8 Belgium
7.3.9 Denmark
7.3.10 Finland
7.3.11 Norway
7.3.12 Lithuania
7.3.13 Latvia
7.3.14 Estonia
7.4 Asia Pacific
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Australia
7.4.5 South Korea
7.5 Latin America
7.5.1 Brazil
7.5.2 Mexico
7.5.3 Argentina
7.5.4 Colombia
7.5.5 Chile
7.5.6 Peru
7.6 Middle East and Africa
7.6.1 South Africa
7.6.2 Saudi Arabia
7.6.3 UAE
7.6.4 Turkey
7.6.5 Egypt
7.6.6 Israel
7.6.7 Kuwait
7.6.8 Qatar
Chapter 8 Company Profiles
8.1 Abbott Laboratories
8.2 ARKRAY
8.3 Ascensia Diabetes Care Holding
8.4 B. Braun Melsungen
8.5 Becton, Dickinson and Company
8.6 Bionime Corporation
8.7 DarioHealth Corp.
8.8 Dexcom
8.9 Dr. Reddy’s Laboratories
8.10 Eli Lilly and Company
8.11 F. Hoffmann-La Roche
8.12 Insulet Corporation
8.13 Medtronic
8.14 Nova Biomedical
8.15 Novo Nordisk
8.16 Pendiq
8.17 Platinum Equity Advisors
8.18 Sanofi
8.19 Sinocare
8.20 Tandem Diabetes Care
8.21 Ypsomed Holding
